Eupraxia Pharmaceuticals 3/19/2026 Earnings Report

Eupraxia Pharmaceuticals EPS Results

• Actual EPS: -$0.37
• Consensus EPS: -$0.16
• Beat/Miss: Missed by -$0.21
• One Year Ago EPS: N/A

Eupraxia Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Eupraxia Pharmaceuticals Announcement Details

• Date: 3/19/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Eupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach.

Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.